NeonMind Biosciences Inc.

09:31 AM EST - NeonMind Biosciences Inc. : Announced that on March 4, 2020 NeonMind engaged Philippe Martin as a drug development consultant. Mr. Martin has 20 years of biotechnology and pharmaceutical industry experience developing and commercializing innovative therapies in the fields of immunology, oncology and neurology. NeonMind has engaged Mr. Martin to advise on drug development programs and recommend critical resources for execution, as well as review and evaluate potential drug development paths to advance NeonMind's two psilocybin drug development programs. "Philippe's proven ability to successfully bring innovative and transformational therapies to market make him an excellent addition to the NeonMind drug development team," says Robert Tessarolo, NeonMind's President and CEO. "Philippe will help us navigate the many decisions we need to make to advance synthetic psilocybin through the rigorous drug development process towards becoming an approved medical therapy." NeonMind Biosciences Inc. shares C.NEON are trading unchanged at $0.28.

Stocks in Play